Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Qiu, Mantang ^a,b   Yang, Xin ^a,b   Hu, Jingwen ^a,b   Ding, Xiangxiang ^a,b   Jiang, Feng ^a   Yin, Rong ^a   Xu, Lin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; BIOLOGICAL MARKER; GLUTAMINE; LYSINE; PLATINUM COMPLEX; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; ERCC2 PROTEIN, HUMAN; PLATINUM DERIVATIVE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN FUNCTION; QUALITY CONTROL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; ETHNOLOGY; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS;

ALLELES; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84896737103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072251     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
3. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909.
4. Bunn PA, Jr., Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100.
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
6. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, et al. (2006) Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4: 548-582.
7. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23-47.
8. Bahl A, Falk S (2001) Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br J Cancer 84: 1143-1145.
9. Bosken CH, Wei Q, Amos CI, Spitz MR (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94: 1091-1099.
10. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601.
11. Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344.
12. de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21: 453-460.
13. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, et al. (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62: 5457-5462.
14. Zhang ZY, Tian X, Wu R, Liang Y, Jin XY (2012) Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 13: 2583-2586.
15. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, et al. (2012) Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7: 973-981.
16. Wu W, Li H, Wang H, Zhao X, Gao Z, et al. (2012) Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 7: e33200.
17. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, et al. (2012) Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14: 207-213.
18. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, et al. (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 72: 370-377.
19. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 7: e38150.
20. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, et al. (2011) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 28: 315-321.
21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
23. Wells G, Shea B, D. OC, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised stud-ies in meta-analyses.
24. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
26. Provencio M, Camps C, Cobo M, De las Penas R, Massuti B, et al. (2012) Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol 70: 883-890.
27. Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, et al. (2012) Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 78: 92-99.
28. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, et al. (2011) Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026.
29. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, et al. (2012) Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 118: 2466-2475.
30. Li D, Zhou Q, Liu Y, Yang Y, Li Q (2012) DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 29: 1622-1628.
31. Ren S, Zhou S, Wu F, Zhang L, Li X, et al. (2012) Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75: 102-109.
32. Liu L, Yuan P, Wu C, Zhang X, Wang F, et al. (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73: 110-115.
33. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, et al. (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71: 191-198.
34. Li F, Sun X, Sun N, Qin S, Cheng H, et al. (2010) Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33: 489-494.
35. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, et al. (2009) Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10: 859-864.
36. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, et al. (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmaco-genomics. J Clin Oncol 27: 3540-3546.
37. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, et al. (2009) DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123.
38. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, et al. (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803.
39. Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, et al. (2006) [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 28: 196-199.
40. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, et al. (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcita-bine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675.
41. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203.
42. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316.
43. Au WW, Salama SA, Sierra-Torres CH (2003) Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 111: 1843-1850.
44. Liu L, Wu J, Zhong R, Wu C, Zou L, et al. (2012) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog.
45. Liu L, Wu C, Wang Y, Zhong R, Duan S, et al. (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6: 1793-1800.
46. Ke J, Zhong R, Zhang T, Liu L, Rui R, et al. (2013) Replication study in Chinese population and meta-analysis supports association of the 5p15.33 locus with lung cancer. PLoS One 8: e62485.
47. Liu L, Wu J, Wu C, Wang Y, Zhong R, et al. (2011) A functional polymorphism (21607 1G-.2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172-5181.
48. Wu J, Liu J, Zhou Y, Ying J, Zou H, et al. (2012) Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 18: 3972-3981.